Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
17 juin 2024 08h00 HE
|
Salarius Pharmaceuticals, Inc.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
12 juin 2024 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22 mars 2024 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
22 févr. 2024 08h00 HE
|
Salarius Pharmaceuticals, Inc.
Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
16 janv. 2024 08h00 HE
|
Salarius Pharmaceuticals, Inc.
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16,...
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
03 janv. 2024 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD...
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
07 nov. 2023 08h30 HE
|
Salarius Pharmaceuticals, Inc.
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8...
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
10 août 2023 16h05 HE
|
Salarius Pharmaceuticals, Inc.
FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore...
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
08 août 2023 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
11 juil. 2023 08h30 HE
|
Salarius Pharmaceuticals, Inc.
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a...